Alliance extended for a further five years
WILMINGTON, Del. and HOUSTON, Oct. 29 /PRNewswire/ -- AstraZeneca and The University of Texas M. D. Anderson Cancer Center today announced they have renewed their collaboration to integrate pre-clinical and clinical research with a view to speeding up access to new medicines of potential benefit to cancer patients.
The collaboration facilitates interactions between physicians and scientists in both organizations to combine resources and expertise in disease intervention whilst providing flexibility to work in a variety of ways and accelerate the development of new treatments. It is unusual in its focus on pre-clinical research and the transition to clinical trials and was the first of its kind for both institutions.
Since its launch in 2005, the collaboration has utilized AstraZeneca's early development portfolio to generate over two dozen joint research projects. Both parties intend to build on these by extending the collaboration for a further five years and broadening its original focus from aerodigestive diseases (head and neck cancers and lung cancer) to include targets with potential in a variety of cancer settings.(1)
Brent Vose, Vice President of AstraZeneca's Oncology Therapy Area said: "AstraZeneca is committed to the research and development of new, targeted anti-cancer therapies to improve the lives of cancer patients.
"We have a number of promising compounds in development and look forward to seeing the results of some key studies throughout the next year.
"Our collaboration with M.D. Anderson has proven our ability to speed up the drug development process without compromising quality and we look forward to building on our joint efforts to date."
Close cooperation in areas of common interest is essential to meet the
challenge of safe, accelerated drug development according to Robert C. Bast
Jr., M.D., Vice President for Translational Research
Copyright©2008 PR Newswire.
All rights reserved